Cramer said after a modest 7% run since its IPO, Quintiles is one stock with a lot of room to run. The company is known as a contract research organization, which means they specialize in assisting drug makers in getting the mountains of data they need to prove their compounds are both safe and effective. What makes Quintiles so exciting is it's trusted by the Food and Drug Administration and has both the size and scale needed to both provide excellent research as well as stifle its smaller competition. That's why Quintiles has been a part of 85% of all central nervous system research and 76% of all oncology research over the past few years. Quintiles plays right into the hands of drug companies focusing on Phase II and Phase III testing, said Cramer, yet the stock still trades for less than its peers. Given a comparable multiple, Quintiles should be a $50 stock, or 16% higher, but the company deserves more than that given its superior growth rate.